HERA crosses over

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 203-204

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; LETTER; METHODOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 79952037834     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70039-0     Document Type: Letter

References (9)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
2. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
3. Gianni L, Dafni U, Gelber R, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, published online Feb 25. 10.1016/S1470-2045(11)70033-X.
4. Spielmann M, Roché H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
5. Perez EA, Suman VJ, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. 32nd San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10-13, 2009. Abstr 80.
6. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2/neu positive early breast cancer patients: BCIRG 006 study. Cancer Res 2009, 69(24 suppl):62.
7. Inoue K, Nakagami K, Mizutani M, et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010, 119:127-136.
8. Gianni L, Pienkowski T, Im Y-H, et al. Neoadjuvant pertuzumab and trastuzumab: antitumor and safety analysis of a randomized phase II study (" Neosphere"). 33rd San Antonio Breast Cancer Synposium; San Antonio, TX, USA; Dec 8-12, 2010. Abstr S3-2.
9. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. 33rd San Antonio Breast Cancer Synposium; San Antonio, TX, USA; Dec 8-12, 2010. Abstr S3-3.